| Year |
Citation |
Score |
| 2019 |
Carvajal-Hausdorf DE, Patsenker J, Stanton KP, Villarroel-Espindola F, Esch A, Montgomery RR, Psyrri A, Kalogeras KT, Kotoula V, Foutzilas G, Schalper KA, Kluger Y, Rimm DL. Multiplexed Measurement of Signaling Targets and Cytotoxic T cells in Trastuzumab-treated Patients using Imaging Mass Cytometry. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30796036 DOI: 10.1158/1078-0432.Ccr-18-2599 |
0.354 |
|
| 2018 |
Carvajal-Hausdorf D, Stanton K, Patsenker J, Villarroel-Espindola F, Esch A, Montgomery R, Psyrri A, Kalogeras K, Kotoula V, Fountzilas G, Schalper K, Kluger Y, Rimm D. Abstract P2-09-18: Multiplexed (18-Plex) measurement of protein targets in trastuzumab-treated patients using imaging mass cytometry Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-09-18 |
0.445 |
|
| 2017 |
Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, et al. Combating subclonal evolution of resistant cancer phenotypes. Nature Communications. 8: 1231. PMID 29093439 DOI: 10.1038/S41467-017-01174-3 |
0.338 |
|
| 2017 |
Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, et al. Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. Plos One. 12: e0186551. PMID 29020035 DOI: 10.1371/Journal.Pone.0186551 |
0.301 |
|
| 2017 |
Hassan S, Esch A, Liby T, Gray JW, Heiser LM. Pathway-enriched gene signature associated with 53BP1 response to PARP inhibition in triple-negative breast cancer. Molecular Cancer Therapeutics. PMID 28958991 DOI: 10.1158/1535-7163.Mct-17-0170 |
0.401 |
|
| 2017 |
Hassan S, Esch A, Heiser LM, Gray JW. Abstract B24: Genomic prediction of response to PARP inhibition in breast cancer Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B24 |
0.416 |
|
| 2017 |
Villarroel-Espindola F, Carvajal-Hausdorf D, Datar I, Esch A, Rashidi N, Nassar A, Ren S, Montgomery RR, Herbst RS, Rimm DL, Schalper KA. Abstract 1635: Multiplexed analysis of fixed tumor tissues using imaging mass cytometry Cancer Research. 77: 1635-1635. DOI: 10.1158/1538-7445.Am2017-1635 |
0.414 |
|
| 2016 |
Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, A Dane M, Esch A, Feiler HS, Wang NJ, et al. Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Research : Bcr. 18: 70. PMID 27368372 DOI: 10.1186/S13058-016-0728-Y |
0.336 |
|
| 2015 |
Esch A, Heiser L, Gray JW. Biological indicators of response and resistance to PARP inhibition in BRCA wild-type breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 125. PMID 28147797 DOI: 10.1200/Jco.2015.33.28_Suppl.125 |
0.354 |
|
| 2015 |
Korkola JE, Collisson EA, Heiser L, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, et al. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. Plos One. 10: e0133219. PMID 26181325 DOI: 10.1371/Journal.Pone.0133219 |
0.365 |
|
| 2010 |
Mastroianni M, Kim S, Kim YC, Esch A, Wagner C, Alexander CM. Wnt signaling can substitute for estrogen to induce division of ERalpha-positive cells in a mouse mammary tumor model. Cancer Letters. 289: 23-31. PMID 19665836 DOI: 10.1016/J.Canlet.2009.07.012 |
0.347 |
|
| Show low-probability matches. |